Trial Profile
A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms Keynote-593
- 11 Oct 2022 Planned End Date changed from 1 Jan 2026 to 22 Jul 2024.
- 11 Oct 2022 Planned primary completion date changed from 1 Jan 2026 to 22 Jul 2024.
- 11 Jul 2022 Status changed from recruiting to active, no longer recruiting.